Belimumab
FDA grants Orphan Drug Designation to belimumab for systemic sclerosis
The FDA has granted Orphan Drug Designation to belimumab, a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis, according to a press release from GlaxoSmithKline.
Belimumab effective for cutaneous lupus erythematosus, regardless of SLE, after 20 weeks
PHILADELPHIA — Belimumab demonstrated a strong clinical response and significantly reduced flare risk for patients with cutaneous lupus erythematosus, with or without systemic lupus erythematosus, after 20 weeks, said a presenter here.
Severe infection risk for lupus lower with belimumab vs. oral immunosuppressants
PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.
Patients with lupus ‘not doing as well as we would like’ despite new therapies
SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.
Belimumab, standard therapy improves outcomes in East Asian patients with lupus nephritis
Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.
‘Comfort level’ driving divide between rheumatologists, nephrologists in lupus nephritis
Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.
Belimumab becomes first FDA-approved drug for pediatric lupus nephritis
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
Q&A: CD6/ALCAM may hold key to more specific, effective therapies in lupus nephritis
Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.
Belimumab after rituximab reduces IgG anti-dsDNA antibody levels, flare risk in lupus
Belimumab after rituximab reduces serum IgG anti-double-stranded DNA antibody levels and the risk for severe flare in systemic lupus erythematosus refractory to conventional therapy, according to data.
Great Debate pits belimumab against voclosporin as first-line therapy for lupus nephritis
Although recent clinical data continue to expand possible treatment options for lupus nephritis, whether belimumab or voclosporin should be the first-line therapy remained hotly contested during the ACR’s annual Great Debate.